Hutchison China Meditech Ltd (HCM)

 

HCM Share PerformanceMore

52 week high2,470.00 14/03/16
52 week low1,612.50 28/04/16
52 week change -147.50 (-6.56%)
4 week volume67,300 01/02/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Chi-Med starts Savolitinib PSC trial in China

Hutchison China MediTech has started a phase II study of savolitinib in locally advanced or metastatic pulmonary sarcom...

Start of Phase II Savolitinib PSC trial in China

RNS Number: 2752X Hutchison China Meditech Limited 20 February 2017 Press Release Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma London: Monday, February 20, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that a Phase II study of savolitinib has been initiated in locally ad...

Start of Phase II Savolitinib PSC trial in China

RNS Number: 2752X Hutchison China Meditech Limited 20 February 2017 Press Release Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma London: Monday, February 20, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that a Phase II study of savolitinib has been initiated in locally ad...

Chi-Med and AZ to present savolitinib results at symposium

Hutchison China MediTech and AstraZeneca will present data from the ongoing phase II clinical trial of savolitinib in pati...

Initiates Phase I of Novel FGFR Inhibitor HMPL-453

RNS Number: 8060W Hutchison China Meditech Limited 14 February 2017 Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia London: Tuesday, February 14, 2017: Hutchison China MediTech Limited ( " Chi-Med " ) (AIM/Nasdaq: HCM) today announces that it has initiated the first-in-human ( " FIH " ) Phase I clinical tr...

Savolitinib PRCC Results Presentation at ASCO GU

RNS Number: 8057W Hutchison China Meditech Limited 14 February 2017 Press Release Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary CancersSymposium London: Tuesday, February 14, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) and AstraZeneca PLC ("AstraZen...

Chi-Med to Announce 2016 Final Results

RNS Number: 9994V Hutchison China Meditech Limited 06 February 2017 Chi-Med to Announce 2016 Final Results London: Monday , February 6, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) will be announcing its final results for the year ended December 31, 2016 on Monday, March 13, 2017 at 7:00 am Greenwich Mean Time (GMT). A...

Change of Directors

RNS Number: 6971V Hutchison China Meditech Limited 01 February 2017 Change of Directors London: Wednesday , February 1, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that with effect from today :- 1. Dr Karen Jean Ferrante has been appointed as Independent Non-Executive Director, Chairman of Technical Com...

Equity Research (HCM)

Hutchison China MediTech Ltd.
03/08/2016
Chi-Med’s CEO, Christian Hogg, delivered a confident and convincing presentation at the recent interim analyst meeting. It was certainly refreshing to hear a CEO explain a drop in profits (and doing...
edison investment research
Hutchison China MediTech Ltd.
27/05/2016
Hutchison China MediTech (Chi-Med) (HCM) is an innovative biopharma company focused on the highly lucrative global oncology and immunology markets. HCM has built a substantial pipeline of potential...
edison investment research
Hutchison China MediTech Ltd.
05/03/2015
The next 12-18 months should be the defining period as Hutchison China MediTech transitions into a fully-fledged pharmaceutical business. Solid FY14 results confirm the continuing growth at China...

Latest discussion posts More

  • Material News due shortly

    1. FY16 Results 13th March 2. Fruquinitinib PIII CRC data and NDA filing - the first ever 3. New Pivotal/final studies:- Savolitinib Phase III in c-Met-driven ...
    26-Feb-2017
    David Global
  • Fruquintinib NDA due soon

    Fruquintinib Colorectal cancer Ph.III complete ; report early 2017; NDA mid 2017 This is what we are really waiting for and will be very material IMO Fruquintinib is ...
    19-Feb-2017
    David Global
  • Re: No impact on sp

    I agree to some extent but if you look at smaller U.S Biotechs you can get 20% on PI or PII data in a day btw, if anyone is interested in recent Nasdaq China Biotech IPO's ...
    15-Feb-2017
    David Global

Users' HoldingsMore

Users who hold Hutchison China Meditech Ltd also hold..
RDS 'B'25%
NATIONAL GRID24%
BP20%
LLOYDS GRP.17%
GLAXOSMITHKLINE17%

Codes & Symbols

ISINKYG4672N1016
SymbolsHCM, LSE:HCM, HCM.L, HCM:LN, LON:HCM, XLON:HCM